Our approach neither recognises nor follows traditional research field boundaries:

  • We use cell culture models to evaluate prostate cancer cell metabolism at various stages of disease development and treatment resistance. We focus especially on role of lipid metabolism and it’s cross links with androgen metabolism, but study also other metabolic routes. Further, we use the cell models to evaluate how established drugs, like cholesterol-lowering statins may affect prostate cancer cells
  • We perform epidemiological studies using population-based datasets to evaluate how usage of drugs that appeared promising in cell culture models associate with prostate cancer risk and prognosis at population level. This gives further proof of clinical significance of the in vitro findings. And vice versa, drugs that appear to have a promising association with prostate cancer outcomes in epidemiological studies are taken for closer evaluation in cell culture studies
  • We perform clinical trials for drugs that have a beneficial effect against prostate cancer metabolism in cell culture studies AND have demonstrated a promising association with favorable disease outcomes in epidemiological studies. Clinical trials serve as the final test of given drug’s efficacy in clinical management of prostate cancer patients